Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA)
CUSIP: G9TY5A101
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Class A Ordinary Shares, par value $0.0001 per share
- Shares outstanding
- 108,236,654
- Total 13F shares
- 35,347,572
- Share change
- -10,384,413
- Total reported value
- $37,112,793
- Price per share
- $1.05
- Number of holders
- 62
- Value change
- -$12,588,212
- Number of buys
- 34
- Number of sells
- 49
Quarterly Holders Quick Answers
What is CUSIP G9TY5A101?
CUSIP G9TY5A101 identifies ZURA - Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP G9TY5A101:
Top shareholders of ZURA - Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BARCLAYS PLC |
3/4/5
13F
|
10%+ Owner · Company |
0.05%
from 13F
|
2,340,240
|
$24,349,729 | — | 09 Jan 2023 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
9.9%
|
6,353,353
|
$8,322,892 | -$888,073 | 30 Jun 2025 | |
| VR Adviser, LLC |
13F
|
Company |
4.6%
|
5,023,166
|
$6,479,884 | — | 31 Mar 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
4.5%
|
4,860,939
|
$6,270,611 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13D/G
13F
|
Company |
7.5%
|
4,672,416
|
$5,653,623 | $0 | 30 Jun 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
|
Company |
4.9%
|
3,217,503
|
$4,633,204 | $0 | 31 Dec 2024 | |
| Someit Sidhu |
3/4/5
|
Director |
—
mixed-class rows
|
1,479,956
mixed-class rows
|
$4,338,550 | — | 21 May 2025 | |
| PFIZER INC |
13D/G
3/4/5
13F
|
Pfizer Inc. 13-5315170 · 10%+ Owner · Company |
4.6%
|
2,970,022
|
$4,276,832 | $0 | 31 Dec 2024 | |
| Deep Track Capital, LP |
13F
|
Company |
3%
|
3,283,783
|
$4,236,080 | — | 31 Mar 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
2.9%
|
3,170,194
|
$4,089,550 | — | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13F
13D/G
|
Company |
3.2%
from 13D/G
|
2,801,184
|
$3,613,527 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
2.5%
|
2,721,752
|
$3,511,060 | — | 31 Mar 2025 | |
| BRAIDWELL LP |
13F
|
Company |
2.3%
|
2,472,806
|
$3,189,920 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.2%
|
2,350,000
|
$3,031,500 | — | 31 Mar 2025 | |
| Allostery Investments LP |
13F
|
Company |
2.2%
|
2,329,384
|
$3,004,905 | — | 31 Mar 2025 | |
| Amit Munshi |
3/4/5
|
Director |
—
mixed-class rows
|
828,384
mixed-class rows
|
$2,433,212 | — | 21 May 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.4%
|
1,536,000
|
$1,981,440 | — | 31 Mar 2025 | |
| Verender S. Badial |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
820,619
mixed-class rows
|
$1,412,827 | — | 08 May 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.92%
|
993,016
|
$1,281,214 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.78%
|
842,158
|
$1,086,384 | — | 31 Mar 2025 | |
| Michael Howell |
3/4/5
|
Chief Scientific Officer and Head of Translational Science |
—
mixed-class rows
|
529,904
mixed-class rows
|
$1,063,813 | — | 18 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.48%
|
522,292
|
$673,757 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.48%
|
520,276
|
$671,156 | — | 31 Mar 2025 | |
| Christopher Cabell |
3/4/5
|
CMO & Head of R&D |
—
class O/S missing
|
162,060
|
$648,240 | — | 18 May 2023 | |
| Arnout Ploos van Amstel |
3/4/5
|
Director |
—
mixed-class rows
|
151,000
mixed-class rows
|
$620,000 | — | 21 May 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.39%
|
422,223
|
$544,668 | — | 31 Mar 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.39%
|
421,229
|
$543,385 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.34%
|
369,358
|
$476,472 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.28%
|
303,573
|
$391,609 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.27%
|
288,601
|
$372,295 | — | 31 Mar 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.21%
|
223,335
|
$288,102 | — | 31 Mar 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.13%
|
144,685
|
$186,643 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.11%
|
122,976
|
$158,639 | — | 31 Mar 2025 | |
| Forefront Analytics, LLC |
13F
|
Company |
0.1%
|
108,308
|
$139,801 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.09%
|
94,055
|
$121,331 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.08%
|
86,900
|
$112,101 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.08%
|
85,917
|
$110,833 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.08%
|
83,909
|
$108,243 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.06%
|
65,042
|
$83,904 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.05%
|
58,961
|
$76,060 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.05%
|
58,853
|
$75,920 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.05%
|
55,702
|
$71,855 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.03%
|
36,577
|
$47,178 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.03%
|
35,968
|
$46,398 | — | 31 Mar 2025 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.03%
|
30,820
|
$39,758 | — | 31 Mar 2025 | |
| INTECH INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.03%
|
29,545
|
$38,113 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.03%
|
28,840
|
$37,204 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
28,794
|
$37,144 | — | 31 Mar 2025 | |
| Corebridge Financial, Inc. |
13F
|
Company |
0.02%
|
24,728
|
$31,899 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.02%
|
24,117
|
$31,111 | — | 31 Mar 2025 |
Institutional Holders of Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA) as of Q2 2025
As of 30 Jun 2025,
Zura Bio Ltd - Class A Ordinary Shares, par value $0.0001 per share (ZURA) was held by
62 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
35,347,572 shares.
The largest 10 holders included
SUVRETTA CAPITAL MANAGEMENT, LLC, JPMORGAN CHASE & CO, VR ADVISER, LLC, GREAT POINT PARTNERS LLC, Pfizer Inc, BRAIDWELL LP, Point72 Asset Management, L.P., Deep Track Capital, LP, ARMISTICE CAPITAL, LLC, and ADAR1 Capital Management, LLC.
This page lists
62
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
74
Q2 2025 holders
62
Holder diff
-12
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.